¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Ä¡·á À¯Çüº°, Åõ¿© °æ·Îº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Estrogen Receptor Positive Breast Cancer Treatment Market, By Drug Class, By Therapy Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1584125
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 303 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®Æ÷Æ® ÇÏÀ̶óÀÌÆ®

¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 198¾ï 1,032¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â CAGR 7.90%·Î È®´ë

¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå - ½ÃÀå ¿ªÇÐ

À¯¹æ¾Ï °ËÁø¡¤Áø´Ü¿¡ ´ëÇÑ ÀǽÄÀÇ Çâ»óÀÌ ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁø

À¯¹æ¾Ï °ËÁø ¹× Áø´Ü¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀÌ Å©°Ô ÃËÁøµÉ °ÍÀÔ´Ï´Ù. ÀÌ´Â ¹Ì±¹ À¯¹æ¾Ï Àç´Ü¿¡ ÀÇÇØ ÀÔÁõµÇ¾úÀ¸¸ç, Á¶±â ¹ß°ßÀ» ÅëÇØ ±¹ÇÑµÈ ´Ü°è¿¡¼­ Áø´ÜµÈ °æ¿ì »ýÁ¸À²ÀÌ 99%±îÁö Áõ°¡ÇÑ´Ù°í º¸°íÇϰí ÀÖ½À´Ï´Ù. À¯¹æ¾Ï ÀνÄÀÇ ´Þ°ú °°Àº ³ë·Â°ú Susan G. Komen°ú °°Àº ´ÜüÀÇ Ä·ÆäÀÎÀº Á¤±âÀûÀÎ °ËÁøÀÇ Á߿伺¿¡ ´ëÇÑ ÀÏ¹Ý ´ëÁßÀÇ Áö½ÄÀ» ³ô¿© Áö³­ 10³â°£ À¯¹æ¾Ï °ËÁøÀ²ÀÌ 30% Áõ°¡ÇÏ´Â °á°ú¸¦ °¡Á®¿Ô½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ ¾Ï Çùȸ´Â À¯¹æ¾ÏÀÇ ¾à 70%°¡ ER ¾ç¼ºÀÓÀ» °­Á¶Çϸç ÀÌ ¾ÆÇü¿¡ ƯȭµÈ Ç¥Àû Ä¡·áÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ ÷´Ü ¼±º° ±â¼ú°ú À¯ÀüÀÚ °Ë»ç¸¦ ÀÏ»ó Áø·á¿¡ µµÀÔÇÔ¿¡ µû¶ó È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¾¾çÇÐÀÇ Áß¿äÇÑ ºÐ¾ßÀÎ ÀÌ ºÐ¾ß ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032) µ¿¾È ¿¬Æò±Õ ¾à 7.90%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾à¹° À¯Çüº°·Î´Â ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü Á¶ÀýÁ¦(SERM)°¡ 22023³â °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Ä¡·á À¯Çüº°·Î´Â 2023³â È£¸£¸ó ¿ä¹ýÀÌ ÁÖ¿ä À¯ÇüÀÔ´Ï´Ù.

Åõ¿© °æ·Îº°·Î´Â 2023³â °æ±¸Á¦°¡ ÁÖ¿ä À¯ÇüÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ÁÖ¿ä ¼öÀÔ¿øÀ̾ú½À´Ï´Ù.

¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·áÁ¦ ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº ¾à¹° À¯Çüº°, Ä¡·á À¯Çüº°, Åõ¿© °æ·Îº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ½ÃÀåÀ¸·Î ±¸ºÐµË´Ï´Ù.

¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü Á¶ÀýÁ¦, ¾Æ·Î¸¶Å¸Á¦ ¾ïÁ¦Á¦, »çÀÌŬ¸° ÀÇÁ¸¼º Ű³ª¾ÆÁ¦(CDK) ¾ïÁ¦Á¦, PI3K ¾ïÁ¦Á¦ µî 4°¡Áö·Î ºÐ·ùµË´Ï´Ù. ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü Á¶ÀýÁ¦(SERM)´Â ER À¯¹æ¾Ï¿¡ ´ëÇÑ È¿°ú°¡ ÀÔÁõµÇ¾î °¡Àå ³ôÀº ¼øÀ§¸¦ Â÷ÁöÇß½À´Ï´Ù. ±× µÚ¸¦ ÀÌ¾î ¾Æ·Î¸¶Å¸Á¦ ¾ïÁ¦Á¦°¡ Æó°æ ÈÄ ¿©¼º¿¡°Ô ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. »çÀÌŬ¸° ÀÇÁ¸¼º Ű³ª¾ÆÁ¦(CDK) ¾ïÁ¦Á¦°¡ °¢±¤À» ¹Þ°í ÀÖ´Â ¹Ý¸é, PI3K ¾ïÁ¦Á¦´Â ´Ù¼Ò ³·Àº ¼øÀ§¸¦ Â÷ÁöÇß½À´Ï´Ù.

½ÃÀåÀº Ä¡·á¹ý À¯Çü¿¡ µû¶ó È£¸£¸ó ¿ä¹ý, È­Çпä¹ý, Ç¥Àû ¿ä¹ý, ¸é¿ª ¿ä¹ý µî 4°¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. È£¸£¸ó ¿ä¹ýÀº ER À¯¹æ¾Ï¿¡ ´ëÇÑ È¿°ú·Î ÀÎÇØ °¡Àå ¿ì¼± ¼øÀ§°¡ ³ô½À´Ï´Ù. Ç¥Àû Ä¡·á´Â Ä¡·áÀÇ Á¤È®¼ºÀ» Á¦°øÇÏ°í ±× µÚ¸¦ ÀÕ½À´Ï´Ù. È­Çпä¹ýÀº 3À§¸¦ Â÷ÁöÇϸç Á¾Á¾ º´¿ëµÇ¸ç, ¸é¿ª ¿ä¹ýÀº ½ÅÈï Ä¡·á¹ýÀÌÁö¸¸ ÇöÀç ÀÌ ºÐ¾ß¿¡¼­´Â Àû¿ëµµ°¡ ³·½À´Ï´Ù.

¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·áÁ¦ ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®

ºÏ¹Ì´Â ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀåÀ» ¼±µµÇϰí ÀÖÀ¸¸ç, À̴ ÷´ÜÈ­µÈ ÀÇ·á ½Ã½ºÅÛ°ú ³ôÀº ÀÎ½Ä ¼öÁØ¿¡ ÈûÀÔÀº ¹Ù Å®´Ï´Ù. ¹Ì±¹Àº National Breast and Cervical Cancer Early Detection Program(¹Ì±¹ À¯¹æ¾Ï ¹× ÀڱðæºÎ¾Ï Á¶±â¹ß°ß ÇÁ·Î±×·¥)°ú °°Àº ±¸»óÀ» ½ÃÇàÇÏ¿© ½ÃÀÛ ÀÌÈÄ 400¸¸ °Ç ÀÌ»óÀÇ °ËÁøÀ» ½Ç½ÃÇÏ¿© Á¶±â¹ß°ßÀ²À» Å©°Ô Çâ»ó½ÃÄ×½À´Ï´Ù. Çϰí ÀÖ½À´Ï´Ù. À¯·´µµ ÀÌ¿¡ ¹ß¸ÂÃß¾î ¿µ±¹°ú °°Àº ±¹°¡¿¡¼­´Â À¯¹æ¾Ï °ËÁø ÇÁ·Î±×·¥ÀÌ Àß Á¤ÂøµÇ¾î ¾à 85%ÀÇ ¿©¼ºµéÀÌ Á¶±â Áø´ÜÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç, ƯÈ÷ ÀϺ»°ú Àεµ¿Í °°Àº ±¹°¡¿¡¼­ À¯¹æ¾Ï ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °¢±¹ Á¤ºÎ´Â ÀÎ½Ä °³¼± Ä·ÆäÀΰú °ËÁø ±¸»óÀ» °­È­ÇÏ´Â µ¥ ÈûÀ» ½ñ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ÀεµÀÇ National Health MissionÀº °ËÁøÀ²À» ³ôÀ̱â À§ÇØ Áö¿ª ±â¹Ý ÇÁ·Î±×·¥À» ½ÃÀÛÇß½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿¡¼­´Â À¯¹æ¾Ï¿¡ ´ëÇÑ Àνİú Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¡Â÷ °³¼±µÇ°í ÀÖÀ¸¸ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡¼­´Â À¯¹æ¾Ï Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ÀÇ·á ÀÎÇÁ¶ó °³¼±°ú ȯÀÚ ±³À°¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.

¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·áÁ¦ ½ÃÀå - °æÀï ±¸µµ:

¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·áÁ¦ ½ÃÀå °æÀï ±¸µµ´Â ºÏ¹ÌÀÇ ÁÖ¿ä ±â¾÷ÀÌ ÁÖµµÇϰí ÀÖÀ¸¸ç, ¾Æ½ºÆ®¶óÁ¦³×Ä«, È­ÀÌÀÚ¿Í °°Àº ±â¾÷ÀÌ Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ¸·Î ¼±µÎ¸¦ ´Þ¸®°í ÀÖ½À´Ï´Ù.2023³â ¾Æ½ºÆ®¶óÁ¦³×Ä«´Â HER2 ¾ç¼º À¯¹æ¾ÏÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ½Å¾à ¿£ÇãÅõ¸¦ Ãâ½ÃÇϰí Á¾¾çÇÐ Æ÷Æ®Æú¸®¿À¸¦ ´õ¿í È®ÀåÇß´Ù, Á¾¾çÇÐ Æ÷Æ®Æú¸®¿À¸¦ ´õ¿í È®ÀåÇß½À´Ï´Ù. À¯·´¿¡¼­´Â ·Î½´°¡ ¿©ÀüÈ÷ Áß¿äÇÑ °æÀïÀÚÀ̸ç, ´Ù¾çÇÑ ¿¬±¸±â°ü°ú Àû±ØÀûÀ¸·Î °øµ¿¿¬±¸¸¦ ÁøÇàÇÏ¿© ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ýÀ» ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ·Î½´¿Í ÄÉÀӺ긮Áö ´ëÇаúÀÇ °øµ¿ ¿¬±¸´Â Ä¡·á È¿°ú¸¦ ¿¹ÃøÇÏ´Â ¹ÙÀÌ¿À¸¶Ä¿¸¦ °³¹ßÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â ³ë¹ÙƼ½º, ´ÙÄÉ´ÙÁ¦¾à µîÀÇ ±â¾÷ÀÌ ¾àÁøÇϰí ÀÖÀ¸¸ç, ³ë¹ÙƼ½º´Â ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¾Ï ºÐ¾ß ÆÄÀÌÇÁ¶óÀÎ È®Àå¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. È­ÀÌÀÚ(Pfizer)ÀÇ Array Biopharma Àμö¿Í °°Àº ÃÖ±Ù ÇÕº´À» ÅëÇØ À¯¹æ¾Ï Ä¡·áÁ¦ °³¹ß ¿ª·®À» °­È­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ER À¯¹æ¾Ï º´¿ë¿ä¹ý¿¡ ÃÊÁ¡À» ¸ÂÃá Á¦ÈÞ°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Çõ½Å°ú Àü·«Àû Á¦ÈÞ¸¦ ÅëÇØ ȯÀÚÀÇ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ ³ë·ÂÇÏ´Â ¾÷üµéÀÌ Ä¡¿­ÇÑ °æÀï ±¸µµ¸¦ Çü¼ºÇϰí ÀÖÀ½À» ½Ã»çÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·áÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á »ê¾÷ ¿¬±¸

Á¦5Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå ±¸µµ

Á¦7Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå - ¾àÁ¦ Ŭ·¡½ºº°

Á¦8Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå - Ä¡·á À¯Çüº°

Á¦9Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå - Åõ¿© °æ·Îº°

Á¦10Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå - Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Estrogen Receptor Positive Breast Cancer Treatment Market size was valued at USD 19,810.32 Million in 2023, expanding at a CAGR of 7.90% from 2024 to 2032.

The Estrogen Receptor Positive Breast Cancer Treatment Market focuses on therapies targeting estrogen receptor-positive (ER+) breast cancer, which constitutes about 70% of all breast cancer cases and significantly influences treatment decisions. Increasing awareness about breast cancer screening and diagnosis is boosting market growth, as evidenced by the American Cancer Society reporting over 300,000 new cases of breast cancer in the U.S. annually. The rise in targeted therapies and the approval of novel drugs like CDK4/6 inhibitors are transforming treatment paradigms. However, challenges such as high treatment costs and the potential for drug resistance can hinder market expansion. Additionally, the lack of access to advanced therapies in low-income regions represents a restraint. Opportunities lie in the development of combination therapies and personalized medicine approaches, particularly in emerging markets where healthcare systems are evolving to incorporate advanced cancer treatment options, potentially improving patient outcomes and driving market dynamics in the coming years.

Estrogen Receptor Positive Breast Cancer Treatment Market- Market Dynamics

Growing Awareness of Breast Cancer Screening and Diagnosis Drives Growth in the Estrogen Receptor Positive Breast Cancer Treatment Market

Growing awareness of breast cancer screening and diagnosis significantly drives growth in the Estrogen Receptor Positive Breast Cancer Treatment Market, as evidenced by the National Breast Cancer Foundation reporting that early detection can increase survival rates to 99% when diagnosed at localized stages. Initiatives like Breast Cancer Awareness Month and campaigns from organizations such as Susan G. Komen have heightened public knowledge about the importance of regular screenings, leading to a 30% increase in mammogram rates in the past decade. Moreover, the American Cancer Society emphasizes that approximately 70% of breast cancers are ER-positive, highlighting the importance of targeted treatments that cater specifically to this subtype. As healthcare providers increasingly integrate advanced screening techniques and genetic testing into routine care, the demand for effective therapies is expected to rise, further propelling market growth in this vital area of oncology.

Estrogen Receptor Positive Breast Cancer Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.90% over the forecast period (2024-2032)

Based on Drug Class segmentation, Selective Estrogen Receptor Modulators (SERMs) were predicted to show maximum market share in the year 2023

Based on Therapy Type segmentation, Hormonal therapy was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Estrogen Receptor Positive Breast Cancer Treatment Market- Segmentation Analysis:

The Global Estrogen Receptor Positive Breast Cancer Treatment Market is segmented on the basis of Drug Class, Therapy Type, Route of Administration, End-User, and Region.

The market is divided into four categories based on Drug Class: Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Cyclin-Dependent Kinase (CDK) Inhibitors, and PI3K Inhibitors. Selective Estrogen Receptor Modulators (SERMs) rank highest due to their established efficacy in treating ER+ breast cancer. Aromatase inhibitors follow, widely used in postmenopausal women. Cyclin-dependent kinase (CDK) inhibitors are gaining prominence, while PI3K inhibitors rank slightly lower in application.

The market is divided into four categories based on Therapy Type: Hormonal Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy. Hormonal therapy holds the highest priority due to its effectiveness for ER+ breast cancer. Targeted therapy follows closely, offering precision in treatment. Chemotherapy ranks third, often used in combination, while immunotherapy, although emerging, currently has a lower application in this context.

Estrogen Receptor Positive Breast Cancer Treatment Market- Geographical Insights

North America leads the Estrogen Receptor Positive Breast Cancer Treatment Market, driven by advanced healthcare systems and high awareness levels among the population. The U.S. has implemented initiatives like the National Breast and Cervical Cancer Early Detection Program, which provided over 4 million screenings since its inception, significantly improving early detection rates. Europe follows closely, where countries like the UK have established robust breast cancer screening programs, leading to approximately 85% of women being diagnosed at an early stage. In the Asia-Pacific region, rising breast cancer incidence, especially in countries like Japan and India, is prompting governments to enhance awareness campaigns and screening initiatives. For instance, India's National Health Mission has launched community-based programs to increase screening rates. Latin America is experiencing a gradual increase in awareness and access to treatment options, while the Middle East & Africa are focusing on improving healthcare infrastructure and patient education to tackle the rising burden of breast cancer, reflecting a growing commitment to address this significant health issue.

Estrogen Receptor Positive Breast Cancer Treatment Market- Competitive Landscape:

The competitive landscape of the Estrogen Receptor Positive Breast Cancer Treatment Market is characterized by key players in North America, where companies like AstraZeneca and Pfizer lead the charge with innovative therapies. In 2023, AstraZeneca launched its new drug, Enhertu, which targets HER2-positive breast cancer, further expanding its oncology portfolio. In Europe, Roche remains a significant competitor, actively collaborating with various research institutions to advance personalized medicine approaches. For example, Roche's collaboration with the University of Cambridge aims to develop predictive biomarkers for treatment efficacy. In the Asia-Pacific region, companies like Novartis and Takeda are making strides, with Novartis investing in expanding its oncology pipeline in emerging markets. Recent mergers, such as Pfizer's acquisition of Array BioPharma, enhance its capabilities in breast cancer treatment development. Additionally, increasing partnerships focused on combining therapies for ER+ breast cancer signal a robust competitive environment, with companies aiming to address the unmet needs of patients through innovation and strategic collaborations.

Recent Developments:

In October 2024, The FDA approved a new three-drug combination for ER-positive, HER2-negative breast cancer, significantly improving progression-free survival. The treatment includes inavolisib, fulvestrant, and palbociclib, effectively targeting PIK3CA mutations in patients resistant to standard therapies.

In June 2024, AstraZeneca's Truqap (capivasertib) and Faslodex (fulvestrant) have been approved in the EU for advanced ER-positive breast cancer patients with specific biomarker alterations. The combination significantly reduces disease progression risk by 50% compared to Faslodex alone, based on CAPItello-291 trial results.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Estrogen Receptor Positive Breast Cancer Treatment Market Overview

2. Executive Summary

3. Estrogen Receptor Positive Breast Cancer Treatment Key Market Trends

4. Estrogen Receptor Positive Breast Cancer Treatment Industry Study

5. Estrogen Receptor Positive Breast Cancer Treatment Market: COVID-19 Impact Analysis

6. Estrogen Receptor Positive Breast Cancer Treatment Market Landscape

7. Estrogen Receptor Positive Breast Cancer Treatment Market - By Drug Class

8. Estrogen Receptor Positive Breast Cancer Treatment Market - By Therapy Type

9. Estrogen Receptor Positive Breast Cancer Treatment Market - By Route of Administration

10. Estrogen Receptor Positive Breast Cancer Treatment Market - By End-User

11. Estrogen Receptor Positive Breast Cancer Treatment Market- By Geography

12. Key Vendor Analysis- Estrogen Receptor Positive Breast Cancer Treatment Industry

13. 360 Degree Analyst View

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â